 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rhumbline Advisers lowered its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE  Free Report) by 12.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 75,260 shares of the...

Rhumbline Advisers Sells 10,633 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

This price move could indicate a change in the trend, and may be a buy signal for investors...

Sage Therapeutics (SAGE, $19.48) price moved above its 50-day Moving Average on November 29, 2023

BNP Paribas Arbitrage SNC reduced its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE  Free Report) by 34.5% in the 2nd quarter, according to the company in its most recent Form 13F...

BNP Paribas Arbitrage SNC Has $2.21 Million Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sage Therapeutics (SAGE, $19.5) price moved above its 50-day Moving Average on November 24, 2023

This indicator may be signaling SAGE's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Sage Therapeutics (SAGE, $19.43) entered Uptrend as Momentum indicator ascends above 0 level on Nov 22, 2023

This price move could indicate a change in the trend, and may be a sell signal for investors...

Sage Therapeutics (SAGE, $19.31) price exceeded its 50-day Moving Average on November 21, 2023

This is a signal that SAGE's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Sage Therapeutics (SAGE, $19.31) Stochastic Oscillator left the overbought zone on November 21, 2023

Artal Group S.A. cut its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE  Free Report) by 33.3% during the second quarter, according to the company in its most recent disclosure...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Artal Group S.A.

Bank of New York Mellon Corp decreased its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE  Free Report) by 5.4% during the second quarter, according to its most recent filing with the...

Bank of New York Mellon Corp Trims Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

This is a Bullish indicator signaling SAGE's price could rise from here. Traders may explore going long the stock or buying call options...

Sage Therapeutics (SAGE, $19.21) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 15, 2023

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Watchers	5,931
52-Wk Low	$16.52
52-Wk High	$59.99

Market Cap	$1.17B
Volume (M)	893,893.00
52-Wk High	$59.99
52-Wk Low	$16.52

Period	Estimated	Reported	Surprise	Result
Q3'23	$-2.68	$-3.37	-25.60%	MISSED
Q2'23	$-2.55	$-2.68	-4.93%	MISSED
Q1'23	$-2.51	$-2.46	1.86%	BEAT
Q4'22	$-2.38	$-2.47	-3.91%	MISSED
Q3'22	$-2.22	$-2.31	-4.23%	MISSED

SAGE Sage Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals